Insys Therapeutics to Present at the 2013 Wells Fargo Securities Healthcare Conference

(firmenpresse) - PHOENIX, AZ -- (Marketwired) -- 06/11/13 -- Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that it will participate in the 2013 Wells Fargo Securities Healthcare Conference in Boston, taking place on June 18-19, 2013.

President and Chief Executive Officer, Michael L. Babich, will participate in a presentation on Tuesday, June 18, 2013 at 1:10 p.m. ET. The presentation will be webcast live and available for replay at the Insys website .

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.



Darryl S. Baker
Chief Financial Officer
Insys Therapeutics, Inc.
(602) 910-2617

John Woolford
Managing Director
Westwicke Partners, LLC
(443) 213-0506

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 11.06.2013 - 20:30 Uhr
Sprache: Deutsch
News-ID 268748
Anzahl Zeichen: 9369

contact information:
Town:

PHOENIX, AZ

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 191 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Insys Therapeutics to Present at the 2013 Wells Fargo Securities Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Insys Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Insys Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track D ...

PHOENIX, AZ -- (Marketwired) -- 10/29/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to its ...

Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies ...

PHOENIX, AZ -- (Marketwired) -- 10/26/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today issued a statement on the Company's use of specialty pharmacies:Insys distributes Subsys through both speci ...

Insys Therapeutics to Report Third Quarter 2015 Results ...

PHOENIX, AZ -- (Marketwired) -- 10/22/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the third quarter 2015 on Thursday, November 5, 2015, before the U.S. financial markets open. ...

Alle Meldungen von Insys Therapeutics